Literature DB >> 11937015

Practical guide to palliative sedation.

John D Cowan1, Teresa W Palmer.   

Abstract

Terminally ill patients want assurance that their symptoms will be controlled as death approaches. Most patients can have a peaceful death with standard palliative care. Some patients approaching death, however, have refractory symptoms such as pain, dyspnea, nausea, and agitated delirium. Palliative sedation (PS), the use of medications to induce sedation in order to control refractory symptoms near death, is a therapeutic option for these patients. The reported frequency of PS use varies greatly, ranging from 5% to 52% of the terminally ill. One concern with PS is its effect on survival. Data suggest that PS does not lead to immediate death, with the median time to death after initiating PS being greater than 1 to 5 days. A number of medications have been used for PS, but midazolam is most commonly reported. PS is distinct from euthanasia because the intent of PS is relief from suffering without death as a required outcome.

Entities:  

Mesh:

Year:  2002        PMID: 11937015     DOI: 10.1007/s11912-002-0022-2

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  59 in total

1.  Sedation in terminally ill patients.

Authors:  J Hardy
Journal:  Lancet       Date:  2000-12-02       Impact factor: 79.321

2.  Do hospice clinicians sedate patients intending to hasten death?

Authors:  T Morita; J Tsunoda; S Inoue; S Chihara
Journal:  J Palliat Care       Date:  1999       Impact factor: 2.250

3.  Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life.

Authors:  S Grond; D Zech; S A Schug; J Lynch; K A Lehmann
Journal:  J Pain Symptom Manage       Date:  1991-10       Impact factor: 3.612

4.  Barbiturates in the care of the terminally ill.

Authors:  R D Truog; C B Berde; C Mitchell; H E Grier
Journal:  N Engl J Med       Date:  1992-12-03       Impact factor: 91.245

5.  On withholding nutrition and hydration in the terminally ill: has palliative medicine gone too far?

Authors:  G M Craig
Journal:  J Med Ethics       Date:  1994-09       Impact factor: 2.903

6.  Sedation for delirium and other symptoms in terminally ill patients in Edmonton.

Authors:  R L Fainsinger; D De Moissac; I Mancini; D Oneschuk
Journal:  J Palliat Care       Date:  2000       Impact factor: 2.250

7.  The last 48 hours of life.

Authors:  I Lichter; E Hunt
Journal:  J Palliat Care       Date:  1990       Impact factor: 2.250

8.  The use of chlorpromazine for symptom control in dying cancer patients.

Authors:  B McIver; D Walsh; K Nelson
Journal:  J Pain Symptom Manage       Date:  1994-07       Impact factor: 3.612

Review 9.  Estimating length of survival in end-stage cancer: a review of the literature.

Authors:  N den Daas
Journal:  J Pain Symptom Manage       Date:  1995-10       Impact factor: 3.612

10.  On withholding artificial hydration and nutrition from terminally ill sedated patients. The debate continues.

Authors:  G M Craig
Journal:  J Med Ethics       Date:  1996-06       Impact factor: 2.903

View more
  10 in total

Review 1.  [Sedation in palliative medicine: Guidelines for the use of sedation in palliative care : European Association for Palliative Care (EAPC)].

Authors:  B Alt-Epping; T Sitte; F Nauck; L Radbruch
Journal:  Schmerz       Date:  2010-08       Impact factor: 1.107

2.  Attitudes on euthanasia, physician-assisted suicide and terminal sedation--a survey of the members of the German Association for Palliative Medicine.

Authors:  H C Müller-Busch; F S Oduncu; S Woskanjan; E Klaschik
Journal:  Med Health Care Philos       Date:  2004

3.  Current debates on end-of-life sedation: an international expert elicitation study.

Authors:  Evangelia Evie Papavasiliou; Sheila Payne; Sarah Brearley
Journal:  Support Care Cancer       Date:  2014-03-20       Impact factor: 3.603

4.  [Indications and use of benzodiazepines in a palliative care unit].

Authors:  S Stiel; N Krumm; O Schroers; L Radbruch; F Elsner
Journal:  Schmerz       Date:  2008-12       Impact factor: 1.107

5.  Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control.

Authors:  Laszlo Karai; Dorothy C Brown; Andrew J Mannes; Stephen T Connelly; Jacob Brown; Michael Gandal; Ofer M Wellisch; John K Neubert; Zoltan Olah; Michael J Iadarola
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

6.  In-service documentation tools and statements on palliative sedation in Germany--do they meet the EAPC framework recommendations? A qualitative document analysis.

Authors:  Stephanie Stiel; Maria Heckel; Britta Christensen; Christoph Ostgathe; Carsten Klein
Journal:  Support Care Cancer       Date:  2015-08-14       Impact factor: 3.603

7.  Continuous deep sedation and homicide: an unsolved problem in law and professional morality.

Authors:  Govert den Hartogh
Journal:  Med Health Care Philos       Date:  2016-06

8.  Sedation in palliative care - a critical analysis of 7 years experience.

Authors:  H Christof Muller-Busch; Inge Andres; Thomas Jehser
Journal:  BMC Palliat Care       Date:  2003-05-13       Impact factor: 3.234

9.  A research study review of effectiveness of treatments for psychiatric conditions common to end-stage cancer patients: needs assessment for future research and an impassioned plea.

Authors:  Ralph J Johnson
Journal:  BMC Psychiatry       Date:  2018-04-03       Impact factor: 3.630

10.  Forensic Toxicological and Medico-Legal Evaluation in a Case of Incongruous Drug Administration in Terminal Cancer Patients.

Authors:  Pascale Basilicata; Pasquale Giugliano; Giuseppe Vacchiano; Angela Simonelli; Rossella Guadagni; Angela Silvestre; Maria Pieri
Journal:  Toxics       Date:  2021-12-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.